Elraglusib is undergoing investigation in an open-label, multicenter, phase 1/2 trial for the treatment of patients with ...
Arnab Basu, MD, MPH, FACP, explains why sensitivity might be higher in urothelial cancer vs other genitourinary cancers.
The N-AVD regimen showed improved progression-free survival and lower toxicity than BV-AVD in advanced Hodgkin lymphoma, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback